The antimitotic effects of Ukrain™, a Chelidonium majus alkaloid derivative, are reversible in vitro

Panzer, Annie; Joubert, Annie M.; Bianchi, Pepita; Seegers, J.C.

doi:10.1016/s0304-3835(99)00375-4

Cited by 23 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar observations were reported for HeLa, Hs27, Graham 293 and Vero cells [23,24]. The resistance profile of Ukrain also differed from those of doxorubicin, 4-OOH-CYC and etoposide (Table 1).…”

Section: Discussionsupporting

confidence: 84%

In-vitro toxicity of Ukrain against human Ewing tumor cell lines

Lanvers-Kaminsky

Nolting²,

Köster³

et al. 2006

Anti-Cancer Drugs

View full text Add to dashboard Cite

Ukrain is advertised by the manufacturer as a drug for alternative cancer cures with high activity against progressive Ewing tumors. Using the MTT assay, we compared the cytotoxicity of Ukrain with the cytotoxicity of N,N',N''-triethylenethiophosphoramide (thioTEPA), Chelidonium majus L. alkaloids, doxorubicin, cyclophosphamide and etoposide against four human Ewing tumor cell lines. In addition, we studied the cytotoxicity of thioTEPA combined with C. majus L. alkaloids after 48, 72 and 96 h. All compounds reduced the growth of Ewing tumor cell lines in a dose-dependent manner. The concentrations that reduced cell growth by 50% ranged between 6.2 and 31.1 micromol/l for Ukrain, 1.9 and 26.1 micromol/l for C. majus L. extract, and 1.7 and 448 micromol/l for thioTEPA. The sensitivity profile of Ukrain was comparable to that of the C. majus L. alkaloids, and different from that of thioTEPA, cyclophosphamide, etoposide and doxorubicin. Overall, doxorubicin was the most cytotoxic drug followed by cyclophosphamide. Ukrain and the C. majus L. alkaloids were slightly more cytotoxic than etoposide, while thioTEPA showed the lowest cytotoxicity. Co-exposure of thioTEPA with C. majus L. alkaloids resulted in additive but not in synergistic cytotoxicity. The in-vitro results indicate that the cytotoxicity of Ukrain against Ewing tumors is comparable to that of etoposide. While the latter can be used on the basis of broad clinical experience and known risk-benefit ratio, Ukrain for the present might be considered as a candidate for subsequent drug development by xenograft studies followed by systematic clinical trials.

show abstract

Section: Discussionsupporting

confidence: 84%

In-vitro toxicity of Ukrain against human Ewing tumor cell lines

Lanvers-Kaminsky

Nolting²,

Köster³

et al. 2006

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…The effect required long exposure to the compound, since the clonogenic sensitivity assays required more than 24 hours in culture to show reproducible death. This accords with the report of Panzer et al, 35 who found that the antimitotic effects of Ukrain were reversible. Although the exact reason for this phenomenon is currently unknown, the doubling time of the HeLa cell line (22 ± 0.2 hours in our laboratory) and confluence-dependent modulation of the effect of Ukrain (Fig.…”

Section: Discussionsupporting

confidence: 81%

NF-κB does not influence the induction of apoptosis by Ukrain

Mendoza

Zamora²,

Gallardo³

et al. 2006

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…There has not been any study in the literature between oxidative-antioxidative factors and ukrain that can be compared with the results of this study. In a study by Panzer et al (33), it was observed that Ukrain is a chemotherapeutic drug which does not seem to cause serious side-effects (33). In another study, it was shown that a relatively higher affinity for Ukrain was observed in tumor tissue and liver, while affinity was lowest in the brain and muscles.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 96%